tirzepatide once weekly is a groundbreaking, once-weekly injectable medication that acts as a dual GIP and GLP-1 receptor agonist. Marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, it mimics Management of type 2 diabetes

Carnitine in the Streptozotocin-Diabetic Rat

The active compound breaks down through a process called hydrolysis, where water molecules attack the peptide bonds that make tirzepatide effective

Because the mechanism of action is identical, the body typically responds in the same way

Polycystic ovary syndrome (PCOS), fatty liver disease, and chronic inflammatory conditions also support eligibility, since semaglutide improves insulin sensitivity and reduces systemic inflammation

They could provide a privileged entry to augment their impact on other physiological pathways that are outside of what their current limited classification implies

It is up to the public to participate in these research studies to help those suffering from elevated Lp(a) levels